Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR1E | P28566 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27754455 | 1.00 | SLC6A2 (0.52) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| SCHEMBL3458915 | 1.00 | SLC6A2 (0.52) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| SCHEMBL2857779 | 0.91 | SLC6A2 (0.61) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| SCHEMBL27787183 | 0.84 | SLC6A2 (0.54) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| SCHEMBL711505 | 0.83 | SLC6A2 (0.48) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| SCHEMBL4960855 | 0.81 | GABRA1 (0.54) | SLC6A2SLC6A4 | |
| SCHEMBL20059292 | 0.81 | TAAR1 (0.47) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| SCHEMBL8977115 | 0.80 | SLC6A2 (0.50) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| SCHEMBL27894267 | 0.80 | SLC6A2 (0.50) | SLC6A2TAAR1SLC6A4SLC6A3MAOA | |
| SCHEMBL19285572 | 0.80 | SLC6A2 (0.50) | SLC6A2TAAR1SLC6A4SLC6A3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200060997-A1 | TARR Receptor Agonists for Sexual Dysfunction | JOHN MCCOY | 2020-02-27 | — | — | US | claimed |
| EP-3478363-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS | Chemapotheca LLC (US) | 2019-05-08 | — | — | EP | claimed |
| EP-3366306-A2 | USE OF SOME PEPTIDES IN DIAGNOSIS AND TREATMENT OF DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-08-29 | — | — | EP | claimed |
| EP-3351262-A1 | CURAGLUTIDE FOR IN TREATMENT OF PREDIABETES, DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-07-25 | — | — | EP | claimed |
| WO-2017147375-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC (US) | 2017-08-31 | — | — | WO | claimed |
| US-20160000815-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CT HOLDINGS PTY LTD (AU) | 2016-01-07 | — | — | US | claimed |
| WO-2014153099-A2 | METHOD FOR USING EXHALED BREATH TO DETERMINE THE PRESENCE OF DRUG | Pulmonary Analytics (US) | 2014-09-25 | — | — | WO | claimed |
| US-20140142140-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2014-05-22 | — | — | US | claimed |
| EP-2729216-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2014-05-14 | — | — | EP | claimed |
| EP-2608794-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | Northeastern University (US) | 2013-07-03 | — | — | EP | claimed |
| EP-2331088-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2011-06-15 | — | — | EP | claimed |
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | claimed |
| WO-2010054286-A2 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | claimed |
| WO-2010015029-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2010-02-11 | — | — | WO | claimed |
| EP-1451156-A4 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO INC (US) | 2005-05-25 | — | — | EP | claimed |
| EP-1450801-A2 | 2-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| EP-1451156-A1 | 4-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2003045313-A2 | 2-AMINOQUINOLINE COMPOUNDS | MERCK & CO. INC. (US) | 2003-06-05 | — | — | WO | claimed |
| WO-2003045920-A1 | 4-AMINOQUINOLINE COMPOUNDS | MERCK & CO., INC. (US) | 2003-06-05 | — | — | WO | claimed |
| WO-2002006826-A1 | SINGLE-PATIENT DRUG TRIALS USED WITH ACCUMULATED DATABASE | OPT-E-SCRIP, INC. (US) | 2002-01-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100172916-A1 | SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS | MC1R, TYR, MITF | SLC6A2 98/4885TAAR1 1451/4885SLC6A4 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.